Form 4: Rhythm Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, sold 902 shares of common stock on February 4, 2025, to cover withholding taxes related to vesting restricted stock units.

Summary

• Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, filed a Form 4 on February 4, 2025.
• The form reports the sale of 902 shares of common stock at a price of $59.43 per share.
• This sale was executed to cover withholding taxes associated with the vesting of restricted stock units.
• Cramer also exercised 2,650 restricted stock units on February 1, 2025.
• Following these transactions, Cramer directly owns 15,248 shares of Rhythm Pharmaceuticals.
• A Power of Attorney was executed on September 25, 2024, granting authority to several individuals to act on Cramer's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (sale of shares for tax purposes) and doesn't indicate any significant positive or negative sentiment. The executive still holds a substantial number of shares.

Positives

• The sale of shares was explicitly for covering tax obligations related to vested restricted stock units, which is a common and expected practice.
• The executive still holds a significant number of shares (15,248), indicating continued alignment with the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. This transaction appears to be a routine sale to cover tax obligations, which is a standard practice. It's important to monitor such transactions in aggregate to assess overall management sentiment.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• Sales of shares to cover tax obligations upon vesting are a typical part of executive financial planning.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also see similar transactions by their executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but given the stated reason (tax obligations), the impact is likely to be minimal.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, RYTM, Pamela J. Cramer, Restricted Stock Units, Share Sale, Beneficial Ownership, Power of Attorney, Executive Compensation, SEC Filing